Ketamine One (NEO:MEDI.AQN) Interim CEO Adam Deffett joined Steve Darling from Proactive to share news the company has agreed to a collaborative partnership with Cognetivity Neurosciences to study and develop assessments for depression and post-traumatic stress disorder.
Defett talks more about the studies which in the initial stage of the partnership, Cognetivity and Ketamineone will partner on two separate clinical studies, one for depression and the second for PTSD.
Deffett also tells Proactive their wholly-owned contract research organization, KGK Science Inc., has successfully assisted its client, to receive new dietary ingredient (NDI) status from the United States FDA. Hofseth Biocare ASA is a leading manufacturer and marketer of unique and innovative marine-derived calcium, protein, collagen, and lipid nutritional supplements.